A Technological Revolution Anchored on the "Distal Cap"

The European Heart Journal(EHJ) recently published a highly forward-looking review that systematically projects the landscape of coronary revascularization in 2040, based on historical trends and current technological breakthroughs. The core thesis is clear: future revascularization will be increasingly personalized, minimally invasive, and technology-driven, with artificial intelligence, omics science, robotic technology, and non-invasive imaging poised to reshape the entire discipline. Amidst this grand transformation, an anatomical structure that appears deceptively modest yet proves critically pivotal - the distal cap of chronic total occlusion (CTO) lesions​ - is emerging from the shadows of conventional imaging to become a key target that determines procedural success and drives technological evolution.

1. From "Imagenomics" to Precision Recognition of the Distal Cap

The article first introduces "Imagenomics" - a novel interdisciplinary concept that deeply integrates imaging technology with omics sciences such as genomics and lipidomics. By leveraging AI to extract quantitative biomarkers, imagenomics enables early risk stratification, helping distinguish which patients truly require mechanical revascularization and which may benefit from pharmacological approaches (exemplified by the EVAPORATE trial, where icosapent ethyl improved coronary physiology assessed by CT-FFR).

Within this expansive framework, the identification of the distal cap is undergoing a paradigm shift - from empirical speculation to AI-driven quantification. In conventional CTO-PCI, the distal cap is often invisible under direct angiographic opacification due to complete occlusion, forcing operators to infer its location and nature indirectly through collateral circulation. By contrast, next-generation AI algorithms (such as the AI-QCPHA software) can analyze 18 features from CCTA images - including plaque burden, calcification density, and delta FFR-CT - to perform three-dimensional reconstruction and quantitative assessment of the distal cap's fibrous composition, degree of calcification, and its relationship with surrounding microvasculature. This means that by 2040, the distal cap will no longer be a gamble in "blind puncture," but a navigable, well-characterized anatomical target.

2. The "Ménage-à-Trois" of Revascularization Decisions and the Anatomical Weight of the Distal Cap

Over the next 15 years, revascularization decisions will rest on the interaction of three factors: the prognosis of angina, physiological indices (FFR, iFR, QFR, FFR-CT, CFR, etc.), and plaque burden. Crucially, the plaque characteristics at the distal cap directly determine how the third factor - plaque burden - is clinically interpreted.

Identifying high-risk (vulnerable) plaques is central to decision-making. Combining CCTA with PET imaging allows assessment of plaque metabolic activity even in heavily calcified lesions. The distal cap, in particular, serves as the concentrated manifestation of plaque vulnerability: when AI tools detect a low-attenuation necrotic core, positive remodeling, or spotty calcification at the distal cap, this anatomical landmark is elevated from a mere "passage barrier" to a "risk signal" - indicating that the CTO lesion not only requires intervention but may also call for a more aggressive strategy (such as atherectomy or laser ablation) rather than simple guidewire crossing.

3. CCTA as a "One-Stop Shop": The Ultimate Visualization of the Distal Cap

By 2025, CCTA had already become a comprehensive diagnostic tool in centers of excellence, providing both anatomical and functional parameters (FFR-CT, SYNTAX score, etc.). The article predicts that by 2040, CCTA will fully replace conventional invasive coronary angiography (ICA), directly guiding PCI or CABG. The FASTTRACK CABG trial has already demonstrated the safety and feasibility of CCTA-only CABG planning.

In this transition, distal cap visualization represents the ultimate test of whether CCTA can truly serve as a "one-stop" replacement for ICA. The advent of photon-counting detector CT (PCD-CT) provides a definitive answer. With a spatial resolution of up to 0.11 mm - surpassing the ~0.2 mm of conventional ICA - PCD-CT can clearly differentiate intralesional hemorrhage, thrombus, and fibrous cap structures. More importantly, PCD-CT can depict stent struts one by one at a resolution of 111 μm, meaning that even when the distal cap is covered by a stent or located beyond a totally occluded segment, it can be precisely delineated. The "donut image" - a novel plaque phenotype discovered through PCD-CT - is a quintessential representation of the complex architecture at the distal cap: high-density calcification encircling a low-attenuation necrotic core, offering unprecedented anatomical insight to the interventionalist.

4. CTO-PCI: The Distal Cap Evolves from "Obstacle" to "Roadmap"

The article dedicates a specific section to the challenges of CTO. Current evidence (limited by small-sample RCTs) does not yet support CTO PCI for improving hard outcomes, but the future trajectory is clear: symptomatic angina or left ventricular dysfunction with viable myocardium will become strong indications for revascularization.

In this evolution, the anatomical localization of the distal cap will dictate the choice of technical approach. The antegrade approach relies on bidirectional confirmation of both the proximal and distal caps; the retrograde approach uses collateral channels to break through the distal cap "in reverse." Combined with radiofrequency perforation and magnetic navigation, the distal cap is no longer a "blind spot" requiring guesswork. Virtual reality (VR) systems can convert CCTA data into patient-specific 3D anatomical models, allowing operators to "step inside" the coronary arteries before the procedure and rehearse distal cap crossing strategies in a virtual space. With 43 RCTs already evaluating extended reality (XR) technologies, VR-based preoperative planning centered on the distal cap may well become the standard workflow for CTO-PCI by 2040.

5. The "Metal-Less Era" and the Redefinition of the Distal Cap

The article forecasts that younger patients with non-calcified, soft, focal, or diffuse plaques will increasingly receive plaque-regression therapies (novel anti-atherosclerotic biologics), reducing the need for mechanical intervention. Elderly patients, facing more calcified lesions, will require atherectomy, laser, or lithotripsy. The global PCI and CABG markets are projected to trend downward, while bioresorbable scaffolds (e.g., magnesium-based scaffolds) and drug-coated balloons (DCBs) will dominate the "metal-less" era.

This shift carries profound implications for the distal cap: in the bioresorbable scaffold era, the distal cap will no longer be subjected to the long-term stimulus of permanent metallic foreign bodies, fundamentally altering the pattern of intimal healing. The ongoing BIOMAG-II trial, comparing third-generation magnesium scaffolds with DES, may redefine the mechanism of restenosis at the distal cap - shifting the paradigm from "chronic inflammatory response induced by metal" to "biologically mediated remodeling during scaffold resorption."

6. The End of Anticoagulation and Distal Cap Thrombotic Risk

Finally, the article looks ahead to the future of anti-P2Y12 and anticoagulation therapy. CD31-mimetic peptide coating technology can "camouflage" implanted devices, mimicking healthy endothelial surfaces to evade recognition by platelets and leukocytes, potentially rendering post-procedural anticoagulation obsolete. This breakthrough is especially significant for CTO-PCI - the microvasculature distal to the distal cap often faces the dual threats of "reperfusion injury" and "distal embolization" after successful recanalization. If CD31 coating can render the scaffold surface "invisible" to the immune system immediately upon deployment, microcirculatory protection beyond the distal cap will be qualitatively enhanced.

Conclusion

From imagenomics to photon-counting CT, from virtual reality planning to metal-free scaffolds, the 2040 vision of coronary revascularization is nothing short of breathtaking. And at the very center of this grand canvas, the distal cap - once a (blurred), dangerous, and deeply uncertain anatomical structure - is being progressively illuminated by AI, ultra-high-resolution imaging, and robotic technologies. It has transformed from a "blind spot" into a "roadmap," from an "obstacle" into an "information source," and ultimately into an indispensable link in the chain of personalized revascularization decision-making. As the article emphatically concludes: technology will redefine cardiovascular medicine, and the "demystification" of the distal cap stands as one of the most vivid footnotes to this redefinition.